Decongestant activity of desloratadine in controlled-allergen-exposure trials

Clinical Drug Investigation

Volumn 22, Issue SUPPL. 2, 2002, Pages 13-20

  Horak, Friedrich ^a   Stübner, Petra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CETIRIZINE; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; PLACEBO; SEROTONIN 1 ANTAGONIST;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; NOSE OBSTRUCTION; NOSE SECRETION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY; RHINORRHEA; SNEEZING;

EID: 0036327764     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222002-00002     Document Type: Article

References (28)

1. Seasonal allergic rhinitis
2. Epidemiology of seasonal and perennial rhinitis: Clinical presentation and medical history
3. Nasal obstruction as a risk factor for sleep-disordered breathing
4. Overview of comorbid associations of allergic rhinitis
5. Otitis media and eustachian tube dysfunction: Connection to allergic rhinitis
6. Airway cooling in asthmatic and nonasthmatic subjects during nasal and oral breathing
7. Effect of the oronasal breathing route on the bronchoconstrictor response to sulfur dioxide in exercising asthmatic subjects
8. Allergic rhinitis and asthma: How important is the link?
9. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis
10. Decongestant activity of desloratadine versus placebo in allergic rhinitis: Results from three single-dose, placebo-controlled, allergen chamber trials
11. Guidelines for bronchoprovocation on the investigation of occupational asthma. Report of the Subcommittee on Bronchoprovocation for Occupational Asthma
12. Allergic rhinitis and its impact on asthma. ARIA workshop report. 7: Diagnosis and management
13. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids
14. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit
15. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis
16. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit
17. Rapid onset of action of desloratadine in patients with seasonal allergic rhinitis
18. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma
19. Efficacy and tolerability of astemizole-D and loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber
20. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion
21. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma
22. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen induced allergic rhinitis in an allergen exposure unit
23. Complications of allergic rhinitis
24. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma
25. Allergy in relation to orofacial dental deformities in children: A review
26. The upper airways: I. Nasal physiology and defense of the lungs
27. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium